Why the study?
New international guidelines regarding hypertension and lipid-lowering therapies, along with emerging evidence in lifestyle and pharmacotherapy, necessitated an updated review of cardiovascular disease primary prevention recommendations.
This review provides an updated comparison of contemporary European and American guidelines for the primary prevention of cardiovascular disease.
Alerts clinicians to transatlantic guideline differences in primary CVD prevention; extends comparative literature without practice change.
Cardiovascular disease remains a substantial concern in terms of global mortality and morbidity, while prevalence of cardiovascular disease is increasing as treatment modalities improve survival. With an ageing population and increasing costs of chronic medical care, primary prevention of cardiovascular disease is an important target for healthcare providers. Since the previous iteration of this paper, new international guidelines have been produced regarding hypertension and lipid lowering therapies, whilst there is a growing body of evidence and new therapies emerging in other areas of lifestyle and pharmacotherapeutic intervention. This review outlines emerging evidence in the field and compares and contrasts contemporary recommendations from European and American guidelines.
No takes yet. Share an insight, caveat, or question.
Stewart et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: